Synthetic Biologics, Inc.

Theriva Biologics, Inc.

Precision Biologics, Inc.

Andrew Bristol

Michael Kaleko

Steven Hubert

Sheila Connelly

Judith A Kantor

Xue-Ping Wang

Christian Furlan Freguia

Lewis Joe Stafford

Xiulian Du

Mark Semenuk

James Gubbins

Ray Stapleton

Cristina Freire

Janos Luka

The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Beta-lactamase formulations and uses thereof

The invention relates to, in part, improved methods for the production of beta-lactamase using() cells. High yield production of beta-lactamase is achieved using methods of the invention.

-based production of beta-lactamase

The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Intestinal alkaline phosphatase formulations

This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Colon and pancreas cancer specific antigens and antibodies

Growing community of inventors

Rockville, MD, United States of America

Andrew Bristol